← Back to all trials
Recruiting
NCT07652047
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Conditions: Obesity & Overweight
Sex: Female
Ages: 18 Years – 55 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 90
Sponsor: Corxel Pharmaceuticals
Location: Corxel Investigational site Las Vegas Nevada
Summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Eligibility Criteria
Inclusion Criteria:
* Male or female, 18-55 years.
* BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \
Source: ClinicalTrials.gov (NCT07652047). StuddyBuddy aggregates publicly available trial information.
